The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

The case for Ozempic as a dementia buster is building. Research published this week has found that GLP-1 drugs are associated with a lower risk of dementia in people with type 2 diabetes.

Ozempic and similar novel diabetes treatments may lower the risk of Alzheimer's disease and related dementias.. This is the conclusion of a pair of studies by research teams from the U.S. and ...

Does Ozempic also hold the secret to a cure for depression and dementia? As Wes Streeting suggests new weight-loss jabs could be given to unemployed people to help them get back into work, doctors ...

“In November 2022, a study revealed that blood pressure drugs that stimulate type 2 and 4 angiotensin II receptors in the brain were associated with lower rates of dementia among new users of ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

GLP-1s – weight-loss drugs like Ozempic, Wegovy, Zepbound and Mounjaro – also may help treat a litany of other health conditions. New research shows they may help reduce the risk of addiction ...

Drugs like Ozempic and Wegovy could slash risk of dementia. ... Meanwhile, researchers in Ireland suggested GLP-1RAs are “associated with a statistically significant reduction in dementia”.

Obese knee arthritis sufferers experienced almost a 50% reduction in knee pain after taking Ozempic as part of a study published last month in the New England ... which are key markers for dementia.